Associations between lower levels of low-density lipoprotein cholesterol and cardiovascular events in very high-risk patients: Pooled analysis of nine ODYSSEY trials of alirocumab versus control

Guidelines recommend high-intensity statins for patients with atherosclerotic cardiovascular disease (ASCVD). Subgroups with comorbidities that increase cardiovascular risk, such as diabetes mellitus (DM), chronic kidney disease (CKD) or polyvascular disease (PoVD), may derive greater absolute benefit from addition of non-statin therapies. We assessed the relationship between lower low-density lipoprotein cholesterol (LDL-C) and major adverse cardiovascular events (MACE) risk reduction during alirocumab phase III ODYSSEY trials among these subgroups.

Source: Atherosclerosis - July 11, 2019 Category: Cardiology Authors: Antonio J. Vallejo-Vaz, Kausik K. Ray, Henry N. Ginsberg, Michael H. Davidson, Robert H. Eckel, L. Veronica Lee, Laurence Bessac, Robert Pordy, Alexia Letierce, Christopher P. Cannon Source Type: research